Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on December 14, 2021. The registrant is incorporated in California and lists its common stock on The Nasdaq Stock Market LLC. The filing serves as a Regulation FD disclosure regarding an Investor Day program held on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on the disclosure of a presentation rather than the release of financial statements.
Material Changes
No material changes to financial results or operations are reported in this document. The filing discloses the furnishing of a slide presentation (Exhibit 99.1) containing information on product development and development plans presented to investors.
Guidance, Outlook, and Risks
- Outlook: The company provided updates on product development and future plans via the Investor Day presentation slides.
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking. Actual results may differ materially due to risks outlined in the company's Form 10-K.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is deemed "furnished" and not "filed" under the Exchange Act, meaning it is not subject to the liability of Section 18 and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the Investor Day presentation slides (Exhibit 99.1) for specific product development timelines and milestones.
- Review the most recent Form 10-K for detailed risk factors and historical financial performance, as this 8-K does not contain financial data.
- Confirm that the "furnished" status of the presentation limits its legal incorporation into future regulatory filings.
- Note the discrepancy between the request metadata ("Insight Molecular Diagnostics Inc.") and the actual registrant name in the filing ("Oncocyte Corporation").